Diagnosing genital warts typically involves a visual examination by a healthcare professional. In some cases, additional tests such as vinegar solution application (which causes warts to turn white) or biopsy may be performed to confirm the diagnosis. Genital warts can appear weeks to months after HPV infection, and in some cases, individuals may not exhibit any symptoms. Treatment options for genital warts aim to remove the visible warts and manage the underlying HPV infection. Topical medications, such as imiquimod or podofilox, can be applied to the warts, promoting their elimination. Cryotherapy, where warts are frozen off, and surgical procedures like laser therapy or excision may also be utilized for wart removal. It is important to note that while treatments can remove visible warts, they do not cure the underlying HPV infection. Regular follow-up and monitoring are recommended, especially for individuals with high-risk HPV types. Moreover, vaccination against HPV is crucial for preventing new infections and reducing the overall burden of genital warts and associated cancers.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : When acute EBV mimics HIV: A case of false positive p24 antigen and low-level HIV antibody reactivity
Smriti Chaudhary, Imperial College Healthcare NHS Trust, United Kingdom
Title : OnePeru: Peruvian bioinformatics platform to contribute to the fight against antimicrobial resistance
Pool Marcos Carbajal, University of San Martin de Porres, Peru
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain